2022 MRF Research and Science Brochure

Melanoma Research Foundation Research Portfolio

The Melanoma Research Foundation (MRF) is the leading non-profit organization dedicated to eradicating melanoma by accelerating medical RESEARCH , while EDUCATING to and ADVOCATING for the melanoma community.

Funding Melanoma Research

The MRF provides emerging and established scientific investigators (from medical students to senior investigative teams) with highly sought-after, peer-reviewed grants across the disciplines of biology, immunology, prevention, diagnosis and treatment. From 1998–2022, we have awarded 255 grants at 83 institutions, totaling over $21 million.

255

GRANTS FUNDED AT 83 INSTITUTIONS

TYPES OF GRANTS FUNDED:

TYPES OF GRANTS PURPOSE

ELIGIBILITY

DURATION

Introduces students early in their careers to clinical/ research opportunities under the mentorship of an investigator engaged in melanoma research Enables young researchers to generate the ground- work that can leverage additional grant funding from other funding bodies

Medical students at an accredited U.S. medical school or institution

1 year

MEDICAL STUDENT

Junior investigators which include: • Postdoctoral fellows with less than five years of postdoctoral experience OR • A research associate, instructor, assistant professor or the equivalent

2 years

CAREER DEVELOPMENT

Encourages proven researchers to continue research on emerging challenges in melanoma

Established researchers, mainly faculty with at least an associate professor appointment

2 years

ESTABLISHED INVESTIGATOR

TEAM Encourages collaboration across academic disciplines in an institution or among multiple institutions

A PI and at least one co-PI, ideally from different institutions

2 years

Junior through established investigators

CLINICAL TRIAL Fosters clinical trials in the melanoma space

2–3 years

Provide donor-directed research funding, MRF-funded grants awarded through partner organizations and support for urgent or specific research needs such as the reopening of labs following the COVID pandemic

OTHER

Varies by grant

Varies

GRANT RECIPIENT

GRANT RECIPIENT

T he MRF grant was instrumental in helping us to advance our melanoma research program and to connect with the melanoma community.

T his grant was the first one I was awarded after finishing my medical training, and tremendously helped establish my academic career.

Scientific Initiatives

Creation of Resources MRF BREAKTHROUGH CONSORTIUM (MRFBC)

Recognizing a need for greater collaboration around translational research, the MRF formed the MRFBC in 2010. The MRFBC is a national network of 22 centers of excellence in melanoma that collaborate to accelerate drug development.

University of Colorado Northwestern University University

of Chicago Ohio State University

University of Pittsburgh

Dana Farber/Harvard Cancer Center Yale University Memorial Sloan Kettering Cancer Center Columbia University New York University University of Pennsylvania/ Wistar Institute

California Pacific Medical Center

University of California San Francisco

St. John’s Cancer Institute

Fox Chase Cancer Center

The Angeles Clinic and Research Center

Georgetown-Lombardi Comprehensive Cancer Center

University of California Los Angeles

Duke University

M.D. Anderson Cancer Center

Moffitt Cancer Center

Virtual Repository A Virtual Specimen Repository has been established with harmonized SOPs to ensure consistency across institutions and trials and over time. Rare Subtype Focus Community United for Research and Education of Ocular Melanoma (CURE OM) In 2011, the MRF launched CURE OM to focus solely on advancing the goals of the ocular melanoma community. To date, CURE OM has provided $2.1 million in research grants, held numerous scientific conferences and educational patient meetings. In 2021, CURE OM launched a first of its kind patient-reported OM registry (www.visionregistry.org) and continues to advocate for the ocular melanoma community to improve the lives of people impacted by this disease. Pediatric and Mucosal/Acral Lentiginous Melanoma Initiatives The MRF has also launched initiatives that focus on pediat- ric and mucosal/acral lentiginous (MM/ALM) melanoma. As such, the MRF is supporting grants focused on pediatric melanoma as well as mucosal melanoma. With respect to

Vanderbilt University

pediatric melanoma, the MRF sponsors an Annual Pediatric Summit each year so that families can come together and learn the latest in medical treatments and research, and find support. With respect to MM/ALM, the MRF provided funding support for a biomarker trial for MM/ALM patients. Support to the Field • Partnership with the Society for Melanoma Research to sponsor annual investigator awards and satellite symposia • Scientific meetings such as the three Brain Metastases Summits to date. • In 2021, the MRF celebrated three physicians with Humanitarian Awards and Legacy Awards at MRF Galas in Denver, New York City and Chicago. Further, due largely to patient suggestions, the MRF has developed a wide array of educational information, downloads for use in the office, links to clinical trials, buddy programs and online support groups. More information about the MRF, its programs and its scientific leadership can be found at www.melanoma.org. Patient Perspective Incorporating a patient-centric approach to the grant review process, a patient review panel ensures that patient and caregiver priorities are reflected in the research funding process.

FUNDING FROM THE MRF HAS RESULTED IN:

236 PUBLICATIONS

484 PRESENTATIONS

9 PATENTS

25 CLINICAL TRIALS

109 GRANTS WITH NEW COLLABORATIONS

65 GRANTS WITH NEW FUNDING SUPPORT

91 MEDICAL STUDENT AWARDS

33 ESTABLISHED INVESTIGATOR AWARDS

96 CAREER DEVELOPMENT AWARDS

11 TEAM AWARDS

TO LEARN MORE, VISIT MELANOMA.ORG/ RESEARCH-SCIENCE

13 SOCIETY FOR MELANOMA RESEARCH AWARDS

5 DONOR-DIRECTED AWARDS

6 OTHER AWARD TYPES

MELANOMA RESEARCH FOUNDATION melanoma.org/research-science 202.347.9675 or 800.673.1290

Page 1 Page 2 Page 3 Page 4

www.melanoma.org

Made with FlippingBook Ebook Creator